Fracturas vertebrales: evaluación, diagnóstico y tratamiento
Revisión del tema
Resumen
Las fracturas vertebrales son una de las fracturas más comunes relacionadas a la fragilidad ósea y son causa de morbilidad importante. Sin embargo, la epidemiología de las fracturas vertebrales difiere de las fracturas osteoporóticas en otros sitios esqueléticos, ya que solo una tercera parte de las fracturas vertebrales son reconocidas clínicamente y detectadas al realizar una metodología de imagen apropiada, ya que un alto porcentaje presenta FV asintomáticas, las cuales no son detectadas hasta realizar una radiografía simple de columna dorso-lumbar. Por otro lado, la identificación de una fractura vertebral como aguda o crónica, benigna o maligna, hace que el médico tratante presente diferentes estrategias terapéuticas. El objetivo de este artículo de revisión es dar al lector información sobre la epidemiología, los costos, los tipos de fracturas vertebrales, que ocurre con las fracturas vertebrales en las enfermedades reumatológicas, como realizar una evaluación radiográfica de las fracturas vertebrales, la identificación acorde a las diferentes metodologías por imagen, y como es el tratamiento adecuado de las mismas.Citas
I. Genant HK, Wu CY, van Kuijk C, Nevitt MC. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res.1993;8(9):1137-48.
II. Clark P, Cons-Molina F, Deleze M, Ragi S, Haddock L, Zanchetta JR, et al. The prevalence of radiographic vertebral fractures in Latin American countries: the Latin American Vertebral Osteoporosis Study (LAVOS). Osteoporos Int 2009; 20: 275-82.
III. Spivacow FR, Sánchez A. Epidemiología y Costos Financieros de la Osteoporosis en Argentina.Actual. Osteol 2010; 6(3):184-193.
IV. Shuhart CR, Yeap SS, Anderson PA, Jankowski LG, Lewiecki EM, Morse LR, et al. Executive Summary of the 2019 ISCD Position De-velopment Conference on Monitoring Treatment, DXA Cross-cali-bration and Least Significant Change, Spinal Cord Injury, Peri-pros-thetic and Orthopedic Bone Health, Transgender Medicine, and Pediatrics. J Clin Densitom. 2019;22(4):453-471.
V. Pothuaud L, Barthe N, Krieg MA, Mehsen N, Carceller P, Hans D. Evaluation of the potential use of trabecular bone score to com-plement bone mineral density in the diagnosis of osteoporosis: a preliminary spine BMD-matched, case-control study. J Clin Densi-tom. 2009;12(2):170–6.
VI. Leib E, Winzenrieth R, Lamy O, Hans D. Comparing bone microar-chitecture by trabecular bone score (TBS) in Caucasian American women with and without osteoporotic fractures. Calcif Tissue Int. 2014;95(3):201-8.
VII. Lamy O, Krieg MA, Stoll D, Aubry-Rozier B, Metzger M, Hans D. The OsteoLaus cohort study: bone mineral density, microarchitecture score and vertebral fracture assessment extracted from a single DXA device in combination with clinical risk factors improve sig-nificantly the identification of women at high risk of fracture. Os-teologie. 2012;21:77-82.
VIII. Rabier B, Heraud A, Grand-Lenoir C, Winzenrieth R, Hans D. A multicentre, retrospective case-control study assessing the role of trabecular bone score (TBS) in menopausal Caucasian women with low areal bone mineral density (BMDa): Analysing the odds of vertebral fracture. Bone. 2010;46(1):176-81.
IX. Schousboe JT, Vo T, Taylor BC, Cawthon PM, Schwartz AV, Bauer DC, et al. Osteoporotic Fractures in Men MrOS Study Research Group. Prediction of Incident Major Osteoporotic and Hip Fractures by Trabecular Bone Score (TBS) and Prevalent Radiographic Vertebral Fracture in Older Men. J Bone Miner Res. 2016 Mar;31(3):690-7.
X. Clark EM, Cummings SR, Schousboe JT. Spinal radiographs in those with back pain-when are they appropriate to diagnose vertebral fractures? Osteoporos Int. 2017;28(8):2293-2297.
XI. Cooper C. The epidemiology of fragility fractures: is there a role for bone quality? Calcif Tissue Int. 1993;53 Suppl 1:S23-6.
XII. Canalis E, Mazziotti G, Giustina A, Bilezikian JP. Glucocorticoid-in-duced osteoporosis: pathophysiology and therapy. Osteoporos Int 2007;18:1319-28.
XIII. Brance ML, Plantalech L. Osteoporosis inducida por glucocorticoi-des: análisis de las guías internacionales de prevención y trata-miento. Actual Osteol 2013; 9(1): 14-27. ISSN: 1669-8975.
XIV. van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000;15: 993-1000.
XV. Adinoff AD, Hollister JR. Steroid-induced fractures and bone loss in patients with asthma. N Engl J Med 1983;309:265-8.
XVI. van Staa TP, Leufkens HG, Cooper C. The epidemiology of corti-costeroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002;13:777-87.
XVII. Bone HG, Bolognese MA, Yuen CK, Kendler DL, Miller PD, Yang YC, et al. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postme-nopausal women with low bone mass. J Clin Endocrinol Metab. 2011;96(4):972-80.
XVIII. Anastasilakis AD, Polyzos SA, Makras P, Aubry-Rozier B, Kaouri S, Lamy O. Clinical Features of 24 Patients With Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases. J Bone Miner Res. 2017;32(6):1291-1296.
XIX. Miller PD, Bolognese MA, Lewiecki EM, McClung MR, Ding B, Aus-tin M, et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long‐term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone. 2008; 43(2):222–9.
XX. Cummings SR, Ferrari S, Eastell R, Gilchrist N, Jensen JB, McClung M, et al. Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREE-DOM Trial and Its Extension. J Bone Miner Res. 2018; 33(2):190-198.
XXI. McClung MR. Cancel the denosumab holiday. Osteoporos Int. 2016;27(5):1677–82.
XXII. Briot K, Geusens P, Em Bultink I, Lems WF, Roux C. Inflammatory diseases and bone fragility. Osteoporos Int. 2017;28(12):3301–3314.
XXIII. van Staa TP, Geusens P, Bijlsma JW, Leufkens HG, Cooper C. Clinical assessment of the long-term risk of fracture in patients with rheu-matoid arthritis. Arthritis Rheum. 2006;54(10):3104–3112.
XXIV. Klop C, de Vries F, Bijlsma JW, Leufkens HG, Welsing PM. Predicting the 10-year risk of hip and major osteoporotic fracture in rheuma-toid arthritis and in the general population: an independent vali-dation and update of UK FRAX without bone mineral density. Ann Rheum Dis. 2016;75(12):2095–2100.
XXV. Lai EL, Huang WN, Chen HH, Hsu CY, Chen DY, Hsieh TY, et al. Ten-year fracture risk by FRAX and osteoporotic fractures in patients with systemic autoimmune diseases. Lupus. 2019; 28(8):945–953.
XXVI. Tong JJ, Xu SQ, Zong HX, Pan MJ, Teng YZ, Xu JH. Prevalence and risk factors associated with vertebral osteoporotic fractures in patients with rheumatoid arthritis [published online ahead of print, 2019 Nov 5]. Clin Rheumatol. 2019;10.1007/s10067-019-04787-9.
XXVII. Ghazi M, Kolta S, Briot K, Fechtenbaum J, Paternotte S, Roux C. Prevalence of vertebral fractures in patients with rheumatoid arthritis: revisiting the role of glucocorticoids. Osteoporos Int. 2012;23(2):581–587.
XXVIII. Davey-Ranasinghe N, Deodhar A. Osteoporosis and verte-bral fractures in ankylosing spondylitis. Curr Opin Rheumatol. 2013;25(4):509–516.
XXIX. Leone A, Marino M, Dell’Atti C, Zecchi V, Magarelli N, Colosimo C. Spinal fractures in patients with ankylosing spondylitis. Rheuma-tol Int. 2016;36(10):1335–1346.
XXX. Ramírez J, Nieto-González JC, Curbelo Rodríguez R, Castañeda S, Carmona L. Prevalence and risk factors for osteoporosis and fractures in axial spondyloarthritis: A systematic review and me-ta-analysis. Semin Arthritis Rheum. 2018;48(1):44–52.
XXXI. Maillefert JF, Aho LS, El Maghraoui A, Dougados M, Roux C. Changes in bone density in patients with ankylosing spondylitis: a two-year follow-up study. Osteoporos Int. 2001;12(7):605–609.
XXXII. Cooper C, Carbone L, Michet CJ, Atkinson EJ, O’Fallon WM, Melton LJ 3rd. Fracture risk in patients with ankylosing spondylitis: a po-pulation based study. J Rheumatol. 1994;21(10):1877–1882.
XXXIII. Maas F, Spoorenberg A, Brouwer E, Schilder AM, Chaudhry RN, et al. Radiographic vertebral fractures develop in patients with ankylo-sing spondylitis during 4 years of TNF-^ blocking therapy. Clin Exp Rheumatol. 2016;34(2):191–199.
XXXIV. Brance ML, Larroudé MS. Masa ósea y fracturas en enfermedades reumatológicas autoinmunes. Rev Arg Reumatol. 2017; 28(1):25-33.
XXXV. Ogdie A, Harter L, Shin D, Baker J, Takeshita J, Choi HK, et al. The risk of fracture among patients with psoriatic arthritis and psoria-sis: a population-based study. Ann Rheum Dis. 2017;76(5):882-885.
XXXVI. Pedreira PG, Pinheiro MM, Szejnfeld VL. Bone mineral density and body composition in postmenopausal women with psoriasis and psoriatic arthritis. Arthritis Res Ther. 2011;13:R16. 37. Rees F, Doherty M, Grainge M, Lanyon P, Davenport G, Zhang W.
XXXVII. Burden of Comorbidity in Systemic Lupus Erythematosus in the UK, 1999-2012. Arthritis Care Res (Hoboken). 2016;68(6):819-827. 38. Bultink IE, Harvey NC, Lalmohamed A, Cooper C, Lems WF, van Staa TP, et al. Elevated risk of clinical fractures and associated risk factors in patients with systemic lupus erythematosus versus matched controls: a population-based study in the United King-dom. Osteoporos Int. 2014;25(4):1275-1283. 39. Tedeschi SK, Kim SC, Guan H, Grossman JM, Costenbader KH.
XXXVIII. Comparative Fracture Risks Among United States Medicaid En-rollees With and Those Without Systemic Lupus Erythematosus.
XXXIX. Arthritis Rheumatol. 2019;71(7):1141–1146.
XL. Bultink IE, Harvey NC, Lalmohamed A, Cooper C, Lems WF, van Staa TP, et al. Elevated risk of clinical fractures and associated risk factors in patients with systemic lupus erythematosus versus matched controls: a population-based study in the United King-dom. Osteoporos Int. 2014;25(4):1275–1283.
XLI. Bultink IE, Lems WF. Lupus and fractures. Curr Opin Rheumatol. 2016;28(4):426–432.
XLII. Schousboe JT. Epidemiology of Vertebral Fractures. J Clin Densitom. 2016;19(1):8-22.
XLIII. Felsenberg D, Silman AJ, Lunt M, Armbrecht G, Ismail AA, Finn JD, et al. Incidence of vertebral fracture in Europe: results from the European Prospective Osteoporosis Study (EPOS). European Pros-pective Osteoporosis Study (EPOS) Group J Bone Miner Res. 2002; 17(4):716-24.
XLIV. Van der Klift M, De Laet CE, McCloskey EV, Hofman A, Pols HA. The incidence of vertebral fractures in men and women: the Rotter-dam Study. J Bone Miner Res. 2002;17(6):1051-6.
XLV. Hernlund E, Svedbom A, Ivergård M, Compston J, Cooper C, Sten-mark J, et al. Osteoporosis in the European Union: medical mana-gement, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associa-tions (EFPIA). Arch Osteoporos. 2013;8:136.
XLVI. Eastell R, Cedel SL, Wahner HW, Riggs BL, Melton LJ. Classification of vertebral fractures. J Bone Miner Res. 1991 Mar;6(3):207-15.
XLVII. Pham T, Azulay-Parrado J, Champsaur P, Chagnaud C, Legré V, Lafforgue P. “Occult” osteoporotic vertebral fractures: vertebral body fractures without radiologic collapse. Spine (Phila Pa 1976). 2005;30(21):2430–2435.
XLVIII. Kim YJ, Chae SU, Kim GD, Park KH, Lee YS, Lee HY. Radiographic De-tection of Osteoporotic Vertebral Fracture without Collapse. J Bone Metab 2013;20(2):89-94.
XLIX. Tokuda O, Harada Y, Ueda T, Ohishi Y, Matsunaga N. Malignant versus benign vertebral compression fractures: can we use bone SPECT as a substitute for MR imaging?. Nucl Med Commun. 2011;32(3):192–198.
L. Aggarwal A, Salunke P, Shekhar BR, Chhabra R, Singh P, Bhattachar-ya A,et al. The role of magnetic resonance imaging and positron emission tomography-computed tomography combined in diffe-rentiating benign from malignant lesions contributing to vertebral compression fractures. Surg Neurol Int. 2013;4(Suppl 5):S323–S326.
LI. Tokuda O, Harada Y, Ueda T, Ohishi Y, Matsunaga N. Malignant versus benign vertebral compression fractures: can we use bone SPECT as a substitute for MR imaging?. Nucl Med Commun. 2011;32(3):192–198.
LII. Mauch JT, Carr CM, Cloft H, Diehn FE. Review of the Imaging Featu-res of Benign Osteoporotic and Malignant Vertebral Compression Fractures. AJNR Am J Neuroradiol. 2018;39(9):1584-1592.
LIII. Prentice RL, Pettinger MB, Jackson RD, Wactawski-Wende J, Lacroix AZ, Chlebowski RT, et al. Health risks and benefits from calcium and vitamin D supplementation: Women’s Health Initiative clini-cal trial and cohort study. Osteoporos Int 2013; 24(2):567-80.
LIV. Oliveri B, Plantalech L, Bagur A, Wittich AC, Rovai G, Pusiol E, et al. Elevada Incidencia de insuficiencia de vitamina D en los adultos sanos mayores de 65 Años en diferentes regiones de la Argentina. Actual Osteol 2005; 1:40-6.
LV. Plantalech L. Mapa de hipovitaminosis D en argentina. Actual Os-teol 2005; 1:11-5.
LVI. Brance ML, Barbosa C, Dappen L, Borquez J, Brun LR. Dose of vi-tamin D required to reach 25-hydroxyvitamin D optimum levels.
LVII. Bone.2015.12.028. Abstract. 57. Maraka S, Kennel KA. Bisphosphonates for the prevention and treatment of osteoporosis. BMJ 2015; 351: h3783.
LVIII. Black DM, Cummings SR, Karpf DB, Cauley A, Thompson DE, Ne-vitt MC, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535-1541.
LIX. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, et al. Effects of risedronate treatment on vertebral and nonver-tebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999; 282(14):1344-52.
LX. Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteopo-rosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int. 2000;11(1):83-91.
LXI. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson De, Ne-vitt MC, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535-1541.
LXII. Chesnut III CH, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004; 19(8):1241-9.
LXIII. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356(18):1809-22.
LXIV. Black DM, Reid IR, Boonen S, Bucci-Rechtweg C, Cauley JA,Cosman F, et al. The effect of 3 versus 6 years of zoledronic acidtreatment of osteoporosis: a randomized extension to theHORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. 2012;27:243–254.
LXV. Black DM, Reid IR, Cauley JA, Cosman F, Leung PC, Lakatos P, et al.The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pi-votal Fracture Trial (PFT). J Bone Miner Res. 2015;30(5):934-44.
LXVI. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 361: 756–65.
LXVII. Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cum-mings SR, et al. 10 years of denosumab treatment in postmeno-pausal women with osteoporosis: results from the phase 3 rando-mised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017;5(7):513-523. 68. Canalis E, Giustina A, Bilezikian JP. Mechanisms of anabolic thera-pies for osteoporosis. N Engl J Med 2007; 357: 905–16. 69. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-41. 70. Chen P, Miller PD, Delmas PD, Misurski DA, Krege JH. Change in lumbar spine BMD and vertebral fracture risk reduction in teripa-ratide-treated postmenopausal women with osteoporosis. J Bone Miner Res 2006;21:1785-90. 71. Black DM, Bilezikian JP, Ensrud KE, Greenspan SL, Palermo L, Hue T, et al. One year of alendronate after one year of parathyroid hormo-ne (1-84) for osteoporosis. N Engl J Med. 2005; 353:555-565. 72. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, et al. The effects of parathyroid hormone and alendronate alo-ne or in combination in postmenopausal osteoporosis. N Engl J Med. 2003; 349:1207-1215. 73. Kim DH, Vaccaro AR. Osteoporotic compression fractures of the spine; current options and considerations for treatment. Spine J. 2006;6(5):479–487.
LXVIII. 74. Evans AJ, Kip KE, Brinjikji W, Layton KF, Jensen ML, Gaughen JR, et al. Randomized controlled trial of vertebroplasty versus kypho-plasty in the treatment of vertebral compression fractures. J Neu-rointerv Surg. 2016;8(7):756-763. 75. Drazin D, Nuno M, Shweikeh F, Vaccaro AR, Baron E, Kim TT, et al.
LXIX. Outcomes and National Trends for the Surgical Treatment of Lum-bar Spine Trauma. Biomed Res Int. 2016;2016:3623875.
Derechos de autor 2020 A nombre de los autores. Derechos de reproducción: Sociedad Argentina de Reumatología
Esta obra está bajo licencia internacional Creative Commons Reconocimiento-NoComercial-SinObrasDerivadas 4.0.
